IKBKB
Overview
IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta, also known as IKK2 or IKK-beta) encodes the catalytic subunit of the IKK complex, which is a key activator of NF-kB signaling. In oral squamous cell carcinoma (OSCC), IKBKB is located within or near the recurrent 11q13 amplicon alongside CCND1, FADD, BIRC2, and BIRC3, contributing to oncogenic signaling through NF-kB pathway activation.
Alterations observed in the corpus
- Located within or near the 11q13 CCND1 amplicon in OSCC with strong copy-number-expression correlation; possibly contributes to oncogenesis alongside CCND1 in this genomic context PMID:23619168
- ABC-selective CRISPR essentiality in DLBCL (B-cell-development/NF-κB signaling); reinforces NF-κB pathway targeting (e.g., BTK inhibitors, IRAK inhibitors) for ABC DLBCL patients in a 1001-patient cohort. PMID:28985567
Cancer types (linked)
- OSCC (Oral Squamous Cell Carcinoma): copy-number gain at the 11q13 locus; co-amplified with CCND1 (22% of OSCC), FADD, BIRC2, and BIRC3 PMID:23619168
Co-occurrence and mutual exclusivity
- Co-amplified with CCND1, FADD, BIRC2, and BIRC3 within the 11q13 amplicon in HNSCC PMID:23619168
Therapeutic relevance
- No specific therapeutic targeting reported in this study; 11q13 amplification context may be relevant for combination strategies in HNSCC PMID:23619168
Open questions
- Functional contribution of IKBKB copy gain distinct from CCND1 amplification at 11q13 remains to be disentangled PMID:23619168
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:28985567
This page was processed by entity-page-writer on 2026-05-15.